Development of mRNA vaccine against Measles virus globally | ||||
| Middle East Journal of Medical Genetics | ||||
| Articles in Press, Accepted Manuscript, Available Online from 24 January 2024 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mxe.2024.241269.1007 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Mohammed M Kassab 
| ||||
| Instructor of microbiology,immunology,faculty of pharmacy,Cairo university,Egypt Specialist of pharmacology, toxicology and clinical pharmacy. | ||||
| Abstract | ||||
| Background: Nowadays, Measles is a dangerous, perhaps fatal viral infection that affects children and newborns in particular. The respiratory tract's mucosal cells are the only area where the infection may first spread before moving on to nearby lymph nodes and eventually, via the blood, to other organs including the skin. Immunity lasts for life. The aim of the study: Widespread utility of the LNP-mRNA Measles vaccine to protect against lethal Measles viral infection. The type of the study: Screening experimental study. Methodology: In the current work, an envelope spike Haemagglutinin protein of Measles vaccine made of lipid nanoparticles was developed. Lipid nanoparticles[ LNPs] with a particle size of around 100 nanometre were used as the drug delivery system for the vaccination. By using a hot micro-emulsion process, lipid nanoparticles were created. Results: In randomized clinical studies including humans, the vaccine's effectiveness was 76%, while in preclinical animal research, it was 90%. Compared to the conventional live attenuated Measles vaccination, it demonstrated equivalent biological activity and fewer side effects. The consequence lasted for a long time. | ||||
| Keywords | ||||
| Measles virus; vaccine; mRNA; infection; prophylaxis | ||||
|
Statistics Article View: 73 |
||||
